Literature DB >> 18366060

LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

Shuji Ogino1, Takako Kawasaki, Katsuhiko Nosho, Mutsuko Ohnishi, Yuko Suemoto, Gregory J Kirkner, Charles S Fuchs.   

Abstract

The CpG island methylator phenotype (CIMP) with widespread promoter CpG island methylation is a phenotype in colorectal cancer, associated with microsatellite instability (MSI) and BRAF mutation. Genome-wide hypomethylation may also play an important role in genomic instability. However, the relation between global DNA methylation level and methylation in individual CpG islands remains uncertain. Utilizing 869 population-based colorectal cancers, we measured long interspersed nucleotide element-1 (LINE-1) methylation level by Pyrosequencing, which correlates with global DNA methylation level. We quantified DNA methylation in 8 CIMP-specific promoters (CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) by real-time PCR (MethyLight technology). LINE-1 methylation levels in tumors were approximately normally distributed (mean, 61.4%; median, 62.3%; standard deviation, 9.6%). Among the 869 tumors, 128 (15%) were classified as CIMP-high (>or=6/8 methylated promoters). The mean LINE-1 methylation level was higher in CIMP-high tumors (65.1%, p < 0.0001) than non-CIMP-high tumors (60.7%), and higher in MSI-high tumors (64.7%, p < 0.0001) than non-MSI-high tumors (60.7%). When tumors were stratified by MSI/CIMP status, compared to non-MSI-high non-CIMP-high tumors (mean LINE-1 methylation level, 60.4%), the mean LINE-1 methylation level was higher in MSI-high CIMP-high (64.8%, p < 0.0001), MSI-high non-CIMP-high (64.6%, p = 0.03) and non-MSI-high CIMP-high tumors (66.1%, p = 0.0003). In addition, 18q loss of heterozygosity in non-MSI-high tumors was correlated with LINE-1 hypomethylation (p = 0.004). In conclusion, both CIMP-high and MSI-high are inversely associated with LINE-1 hypomethylation, suggesting that CIMP/MSI and genomic hypomethylation may represent different pathways to colorectal cancer. Our data also support a possible link between global hypomethylation and chromosomal instability. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18366060      PMCID: PMC2630175          DOI: 10.1002/ijc.23470

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  48 in total

1.  CIMP and colon cancer gets more complicated.

Authors:  William M Grady
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

2.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.

Authors:  Daniel J Weisenberger; Kimberly D Siegmund; Mihaela Campan; Joanne Young; Tiffany I Long; Mark A Faasse; Gyeong Hoon Kang; Martin Widschwendter; Deborah Weener; Daniel Buchanan; Hoey Koh; Lisa Simms; Melissa Barker; Barbara Leggett; Joan Levine; Myungjin Kim; Amy J French; Stephen N Thibodeau; Jeremy Jass; Robert Haile; Peter W Laird
Journal:  Nat Genet       Date:  2006-06-25       Impact factor: 38.330

3.  Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.

Authors:  Shuji Ogino; Robert D Odze; Takako Kawasaki; Mohan Brahmandam; Gregory J Kirkner; Peter W Laird; Massimo Loda; Charles S Fuchs
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

4.  Silencing of the UCHL1 gene in human colorectal and ovarian cancers.

Authors:  Eriko Okochi-Takada; Kazuyuki Nakazawa; Mika Wakabayashi; Akiko Mori; Shizue Ichimura; Toshiharu Yasugi; Toshikazu Ushijima
Journal:  Int J Cancer       Date:  2006-09-15       Impact factor: 7.396

5.  MethyLight: a high-throughput assay to measure DNA methylation.

Authors:  C A Eads; K D Danenberg; K Kawakami; L B Saltz; C Blake; D Shibata; P V Danenberg; P W Laird
Journal:  Nucleic Acids Res       Date:  2000-04-15       Impact factor: 16.971

6.  APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer.

Authors:  Barry Iacopetta; Fabienne Grieu; Wei Li; Andrew Ruszkiewicz; Maria Caruso; James Moore; Goh Watanabe; Kazuyuki Kawakami
Journal:  Int J Cancer       Date:  2006-11-15       Impact factor: 7.396

7.  Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.

Authors:  Jairo Rodriguez; Jordi Frigola; Elisenda Vendrell; Rosa-Ana Risques; Mario F Fraga; Cristina Morales; Victor Moreno; Manel Esteller; Gabriel Capellà; Maria Ribas; Miguel A Peinado
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

8.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.

Authors:  S Ogino; M Cantor; T Kawasaki; M Brahmandam; G J Kirkner; D J Weisenberger; M Campan; P W Laird; M Loda; C S Fuchs
Journal:  Gut       Date:  2006-01-11       Impact factor: 23.059

Review 9.  CpG island methylator phenotype in cancer.

Authors:  Jean-Pierre Issa
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

10.  Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations.

Authors:  Sarah Derks; Cindy Postma; Beatriz Carvalho; Sandra M van den Bosch; Peter T M Moerkerk; James G Herman; Matty P Weijenberg; Adriaan P de Bruïne; Gerrit A Meijer; Manon van Engeland
Journal:  Carcinogenesis       Date:  2007-11-28       Impact factor: 4.944

View more
  147 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

2.  Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Authors:  Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

3.  Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis.

Authors:  Zhong-Zheng Zhu; Lifang Hou; Valentina Bollati; Letizia Tarantini; Barbara Marinelli; Laura Cantone; Allen S Yang; Pantel Vokonas; Jolanta Lissowska; Silvia Fustinoni; Angela C Pesatori; Matteo Bonzini; Pietro Apostoli; Giovanni Costa; Pier Alberto Bertazzi; Wong-Ho Chow; Joel Schwartz; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2010-09-15       Impact factor: 7.196

4.  DNA methylation in the rectal mucosa is associated with crypt proliferation and fecal short-chain fatty acids.

Authors:  Daniel L Worthley; Vicki L J Whitehall; Richard K Le Leu; Natsumi Irahara; Ronald L Buttenshaw; Kylie-Ann Mallitt; Sonia A Greco; Ingunn Ramsnes; Jean Winter; Ying Hu; Shuji Ogino; Graeme P Young; Barbara A Leggett
Journal:  Dig Dis Sci       Date:  2010-07-16       Impact factor: 3.199

5.  MicroRNA MIR21 and T Cells in Colorectal Cancer.

Authors:  Kosuke Mima; Reiko Nishihara; Jonathan A Nowak; Sun A Kim; Mingyang Song; Kentaro Inamura; Yasutaka Sukawa; Atsuhiro Masuda; Juhong Yang; Ruoxu Dou; Katsuhiko Nosho; Hideo Baba; Edward L Giovannucci; Michaela Bowden; Massimo Loda; Marios Giannakis; Adam J Bass; Glenn Dranoff; Gordon J Freeman; Andrew T Chan; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Cancer Immunol Res       Date:  2015-09-29       Impact factor: 11.151

Review 6.  New trends in molecular and cellular biomarker discovery for colorectal cancer.

Authors:  Parisa Aghagolzadeh; Ramin Radpour
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

7.  Sensitive quantitative analysis of murine LINE1 DNA methylation using high resolution melt analysis.

Authors:  Michelle Newman; Benjamin J Blyth; Damian J Hussey; Daniel Jardine; Pamela J Sykes; Rebecca J Ormsby
Journal:  Epigenetics       Date:  2012-01-01       Impact factor: 4.528

8.  Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.

Authors:  Dan He; Yi-wang Zhang; Na-na Zhang; Lu Zhou; Jian-ning Chen; Ye Jiang; Chun-kui Shao
Journal:  Med Oncol       Date:  2015-02-27       Impact factor: 3.064

9.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.

Authors:  Kosuke Mima; Reiko Nishihara; Zhi Rong Qian; Yin Cao; Yasutaka Sukawa; Jonathan A Nowak; Juhong Yang; Ruoxu Dou; Yohei Masugi; Mingyang Song; Aleksandar D Kostic; Marios Giannakis; Susan Bullman; Danny A Milner; Hideo Baba; Edward L Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Wendy S Garrett; Curtis Huttenhower; Matthew Meyerson; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino
Journal:  Gut       Date:  2015-08-26       Impact factor: 23.059

Review 10.  Epigenetics and colorectal cancer.

Authors:  Victoria Valinluck Lao; William M Grady
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-18       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.